Skip to Main content Skip to Navigation
Journal articles

ST2 in heart failure with preserved and reduced ejection fraction

Abstract : Objectives - Soluble suppression of tumorigenecity 2 (sST2) is prognostic in acute and chronic heart failure with reduced ejection fraction (HFrEF) but less studied in HF with preserved EF (HFpEF). We evaluated sST2 concentrations, correlations with biomarkers and echocardiographic measures of diastolic and systolic function, and associations with outcomes in HFpEF and HFrEF. Design and results - A total of 193 subjects from three different cohorts were included. Eighty-six HFpEF patients were obtained from the Karolinska Rennes (KaRen) study, 86 patients with HFrEF were recruited from referrals to Karolinska University Hospital for advanced assessment of HF, and 21 controls were included ( Identifier for KaRen: NCT01091467). HFrEF and controls cohorts did not have registrations. sST2 was lower in HFpEF, median (interquartile range); 23 (17-31) compared to HFrEF; 35 (23-52) µg/L, p < .001. In both HFpEF and HFrEF, sST2 correlated positively with NT-proBNP (HFpEF r=0.392, p < .001 and HFrEF r=0.466, p < .001). In HFpEF, sST2 correlated to left atrial volume index (r=0.276, p = .019) but not to E/E´, nor to left ventricular mass index. sST2 was in HFpEF associated with the composite endpoint of death or HF hospitalization, adjusted hazard ratio (HR) per log increase in sST2 6.62, 95% confidence interval (CI) 1.04-42.28, p = .046, and in HFrEF death, heart transplant or left ventricular assist systems; 3.51, 95% CI 1.05-11.69, p = .041. Conclusions - In patients with HFpEF compared to HFrEF, crude levels of sST2 were lower but potentially more strongly associated with outcomes. The lower levels of sST2 in HFpEF than in HFrEF may reflect lower degrees of fibrosis, but the potentially stronger association with outcomes may reflect a greater prognostic importance of progressive fibrosis and as such a greater potential for intervention. In conclusion; this study adds to the evidence of sST2 as prognostic marker in both HFpEF and HFrEF.
Keywords : sST2 HFrEF HFpEF
Document type :
Journal articles
Complete list of metadata
Contributor : Laurent Jonchère Connect in order to contact the contributor
Submitted on : Tuesday, February 26, 2019 - 3:30:30 PM
Last modification on : Thursday, January 14, 2021 - 11:16:54 AM

Links full text



Emil Najjar, Ulrika Ljung Faxén, Camilla Hage, Erwan Donal, Jean-Claude Daubert, et al.. ST2 in heart failure with preserved and reduced ejection fraction. Scandinavian Cardiovascular Journal, Taylor & Francis, 2019, 53 (1), pp.21-27. ⟨10.1080/14017431.2019.1583363⟩. ⟨hal-02049702⟩



Les métriques sont temporairement indisponibles